Tango Therapeutics, Inc.

BCTG Acquisition Corp, a blank-check company sponsored by Boxer Capital and focused on the biotechnology and life sciences sector, completed its initial public offering in 2020 and subsequently entered into a business combination with Tango Therapeutics, Inc., a precision oncology company developing targeted cancer medicines. The merger closed in 2021, bringing Tango Therapeutics to public markets under the BCTG ticker on Nasdaq. The 10-Q filed August 9, 2021, with accession number 0001213900-21-040828, reflects the combined company's early post-merger financial position. Investors and analysts seeking deeper data on BCTG and the broader SPAC universe are invited to sign up for full coverage at SpacDesk.